Has anyone else noticed that recent PRs seem to be timed only after they know something for sure? They issued a PR that they had licensed HemaX to research center in Mexico and then less than 10 days later we got a PR on the 1 month test results. In other words, they were only going to let us know about it if it was successful.
Then we get PR on May 24th that they have filed to uplist and on May 31st it is already included on the uplisted tickers.
Seems to me that PRs are being delayed and released upon assurance of positive results, even though many reiterate here the obligation of reporting negative results within 4 days. Orphan Drug status was applied for back in Jan with 90 days being the seemingly maximum time it takes for a response. With the IND already approved, why would it take any longer and if approved, why not state so when you need money?
I can't answer, but my only hope is that it has been approved and they have been working on some deal that needed assurance that their filings and status are okay with SEC and therefore the funding was dependent on uplisting to OTCQB where such reporting status is needed and reflected as a positive for those companies. And that we will therefore hear much more within the next 2 weeks.
This is complete conjecture, but about the only positive spin I can put on not hearing about Orphan Drug Status, not hearing about dCellVax IND data submittal, not hearing any news about new NR2F6 IND (past 30 days) etc.
With 7 more months in the year, I concur that unless by end of year there are substantial developments (clinical trial initiated, a 2nd IND approved etc), RGBP will be much lower at end of year than it began with little reason to hope we can trust what is going on behind the scenes.
